UNLABELLED: Ectodomain shedding of tumor necrosis factor receptor 1 (TNFR1) provides negative feedback to the inflammatory loop induced by TNFα. As the significance of this mechanism in obesity-associated pathologies is unclear, we aimed to unravel how much TNFR1 ectodomain shedding controls the development of nonalcoholic fatty liver disease (NAFLD), as well as its role in the development of insulin resistance. We used knockin mice expressing a mutated TNFR1 ectodomain (p55(Δns)), incapable of shedding and dampen the inflammatory response. Our data show that persistent TNFα signaling through this inability of TNFR1 ectodomain shedding contributes to chronic low-grade inflammation, which is confined to the liver. In spite of this, hepatic lipid levels were not affected by the nonshedding mutation in mice fed a chow diet, nor were they worse off following 12 weeks of high-fat diet (HFD) than controls (p55(+/+)) fed an HFD. We detected inflammatory infiltrates, hepatocellular necrosis, and apoptosis in livers of p55(Δns/Δns) mice fed an HFD, suggesting advanced progression of NAFLD toward nonalcoholic steatohepatitis (NASH). Indeed, fibrosis was present in p55(Δns/Δns) mice, but absent in wildtype mice, confirming that the p55(Δns/Δns) mice had a more severe NASH phenotype. Despite low-grade hepatic inflammation, insulin resistance was not observed in p55(Δns/Δns) mice fed a chow diet, and HFD-induced insulin resistance was no worse in p55(Δns/Δns) mice than p55(+/+) mice. CONCLUSION: TNFR1 ectodomain shedding is not an essential feedback mechanism in preventing the development of hepatic steatosis or insulin resistance. It is, however, pivotal in attenuating the progression from "simple steatosis" towards a more serious phenotype with many NASH features. Targeting TNFR1 could therefore be beneficial in attenuating NASH.
UNLABELLED: Ectodomain shedding of tumor necrosis factor receptor 1 (TNFR1) provides negative feedback to the inflammatory loop induced by TNFα. As the significance of this mechanism in obesity-associated pathologies is unclear, we aimed to unravel how much TNFR1 ectodomain shedding controls the development of nonalcoholic fatty liver disease (NAFLD), as well as its role in the development of insulin resistance. We used knockin mice expressing a mutated TNFR1 ectodomain (p55(Δns)), incapable of shedding and dampen the inflammatory response. Our data show that persistent TNFα signaling through this inability of TNFR1 ectodomain shedding contributes to chronic low-grade inflammation, which is confined to the liver. In spite of this, hepatic lipid levels were not affected by the nonshedding mutation in mice fed a chow diet, nor were they worse off following 12 weeks of high-fat diet (HFD) than controls (p55(+/+)) fed an HFD. We detected inflammatory infiltrates, hepatocellular necrosis, and apoptosis in livers of p55(Δns/Δns) mice fed an HFD, suggesting advanced progression of NAFLD toward nonalcoholic steatohepatitis (NASH). Indeed, fibrosis was present in p55(Δns/Δns) mice, but absent in wildtype mice, confirming that the p55(Δns/Δns) mice had a more severe NASH phenotype. Despite low-grade hepatic inflammation, insulin resistance was not observed in p55(Δns/Δns) mice fed a chow diet, and HFD-induced insulin resistance was no worse in p55(Δns/Δns) mice than p55(+/+) mice. CONCLUSION:TNFR1 ectodomain shedding is not an essential feedback mechanism in preventing the development of hepatic steatosis or insulin resistance. It is, however, pivotal in attenuating the progression from "simple steatosis" towards a more serious phenotype with many NASH features. Targeting TNFR1 could therefore be beneficial in attenuating NASH.
Authors: F Sheedfar; M Vermeer; V Pazienza; J Villarroya; F Rappa; F Cappello; G Mazzoccoli; F Villarroya; H van der Molen; M H Hofker; D P Koonen; M Vinciguerra Journal: Int J Obes (Lond) Date: 2014-05-21 Impact factor: 5.095
Authors: N Turner; G M Kowalski; S J Leslie; S Risis; C Yang; R S Lee-Young; J R Babb; P J Meikle; G I Lancaster; D C Henstridge; P J White; E W Kraegen; A Marette; G J Cooney; M A Febbraio; C R Bruce Journal: Diabetologia Date: 2013-04-26 Impact factor: 10.122
Authors: Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson Journal: Am J Physiol Endocrinol Metab Date: 2018-03-06 Impact factor: 4.310
Authors: Jinhui Li; Teryn N Sapper; Eunice Mah; Swetha Rudraiah; Kevin E Schill; Chureeporn Chitchumroonchokchai; Meredith V Moller; Joshua D McDonald; Philip R Rohrer; José E Manautou; Richard S Bruno Journal: Mol Nutr Food Res Date: 2016-02-18 Impact factor: 5.914
Authors: Nanda Gruben; Anouk Funke; Niels J Kloosterhuis; Marijke Schreurs; Fareeba Sheedfar; Rick Havinga; Sander M Houten; Ronit Shiri-Sverdlov; Bart van de Sluis; Jan Albert Kuivenhoven; Debby P Y Koonen; Marten H Hofker Journal: J Diabetes Res Date: 2015-02-28 Impact factor: 4.011
Authors: Roel A van der Heijden; Fareeba Sheedfar; Martine C Morrison; Pascal P H Hommelberg; Danny Kor; Niels J Kloosterhuis; Nanda Gruben; Sameh A Youssef; Alain de Bruin; Marten H Hofker; Robert Kleemann; Debby P Y Koonen; Peter Heeringa Journal: Aging (Albany NY) Date: 2015-04 Impact factor: 5.682
Authors: M G M Wolfs; N Gruben; S S Rensen; F J Verdam; J W Greve; A Driessen; C Wijmenga; W A Buurman; L Franke; L Scheja; D P Y Koonen; R Shiri-Sverdlov; T W van Haeften; M H Hofker; J Fu Journal: Nutr Diabetes Date: 2015-02-09 Impact factor: 5.097
Authors: Diana Jurk; Caroline Wilson; João F Passos; Fiona Oakley; Clara Correia-Melo; Laura Greaves; Gabriele Saretzki; Chris Fox; Conor Lawless; Rhys Anderson; Graeme Hewitt; Sylvia Lf Pender; Nicola Fullard; Glyn Nelson; Jelena Mann; Bart van de Sluis; Derek A Mann; Thomas von Zglinicki Journal: Nat Commun Date: 2014-06-24 Impact factor: 14.919